

ALCLOMETASONE DIPROPIONATE- alclometasone dipropionate cream
E. Fougera & Co. a division of Fougera Pharmaceuticals Inc.

ALCLOMETASONE DIPROPIONATE CREAM USP, 0.05%


Rx only

For Dermatologic Use Only

Not for Ophthalmic Use

DESCRIPTION:

Alclometasone dipropionate cream contains alclometasone dipropionate (7 α -chloro-11 β ,17,21-trihydroxy-16 α -methylpregna-1,4-diene-3,20-dione 17,21-dipropionate), a synthetic corticosteroid for topical dermatologic use. The corticosteroids constitute a class of primarily synthetic steroids used topically as anti-inflammatory and antipruritic agents. Chemically, alclometasone dipropionate is C₂₈H₃₇ClO₇. It has the following structural formula:



Alclometasone dipropionate has the molecular weight of 521. It is a white powder, insoluble in water, slightly soluble in propylene glycol, and moderately soluble in hexylene glycol. Each gram of alclometasone dipropionate cream contains 0.5 mg of alclometasone dipropionate in a hydrophilic, emollient cream base of propylene glycol, white petrolatum, cetostearyl alcohol, glyceryl monostearate, PEG 100 stearate, ceteth-20, monobasic sodium phosphate, chlorocresol, phosphoric acid, and purified water.

CLINICAL PHARMACOLOGY:

Like other topical corticosteroids, alclometasone dipropionate has anti-inflammatory, antipruritic, and vasoconstrictive properties. The mechanism of the anti-inflammatory activity of the topical steroids, in general, is unclear. However, corticosteroids are thought to act by the induction of phospholipase A₂ inhibitory proteins, collectively called lipocortins. It is postulated that these proteins control the biosynthesis of potent mediators of inflammation such as prostaglandins and leukotrienes by inhibiting the release of their common precursor, arachidonic acid. Arachidonic acid is released from membrane phospholipids by phospholipase A₂.

Pharmacokinetics: The extent of percutaneous absorption of topical corticosteroids is determined by many factors, including the vehicle and the integrity of the epidermal barrier. Occlusive dressings with hydrocortisone for up to 24 hours have not been demonstrated to increase penetration; however, occlusion of hydrocortisone for 96 hours markedly enhances penetration. Topical corticosteroids can be absorbed from normal intact skin. Inflammation and/or other disease processes in the skin may increase percutaneous absorption. A study utilizing a radio labeled alclometasone dipropionate cream

formulation was performed to measure systemic absorption and excretion. Results indicated that approximately 3% of the steroid was absorbed during 8 hours of contact with intact skin of normal volunteers. Studies performed with alclometasone dipropionate cream indicate that this product is in the low to medium range of potency as compared with other topical corticosteroids.

INDICATIONS AND USAGE:

Alclometasone dipropionate cream is a low to medium potency corticosteroid indicated for the relief of the inflammatory and pruritic manifestations of corticosteroid-responsive dermatoses. Alclometasone dipropionate cream may be used in pediatric patients 1 year of age or older, although the safety and efficacy of drug use for longer than 3 weeks have not been established (see **PRECAUTIONS: Pediatric Use**). Since the safety and efficacy of alclometasone dipropionate cream have not been established in pediatric patients below 1 year of age, the use in this age-group is not recommended.

CONTRAINDICATIONS:

Alclometasone dipropionate cream is contraindicated in those patients with a history of hypersensitivity to any of the components in these preparations.

PRECAUTIONS:

General: Systemic absorption of topical corticosteroids can produce reversible hypothalamic-pituitary-adrenal (HPA) axis suppression with the potential for glucocorticosteroid insufficiency after withdrawal of treatment. Manifestations of Cushing's syndrome, hyperglycemia, and glucosuria can also be produced in some patients by systemic absorption of topical corticosteroids while on treatment. Patients applying a topical steroid to a large surface area or to areas under occlusion should be evaluated periodically for evidence of HPA axis suppression. This may be done by using the ACTH stimulation, A.M. plasma cortisol, and urinary free cortisol tests. The effects of alclometasone dipropionate cream on the HPA axis have been evaluated. In one study, alclometasone dipropionate cream was applied to 30% of the body twice daily for 7 days, and occlusive dressings were used in selected patients either 12 hours or 24 hours daily. In another study, alclometasone dipropionate cream was applied to 80% of the body surface of normal subjects twice daily for 21 days with daily 12-hour periods of whole body occlusion. Average plasma and urinary free cortisol levels and urinary levels of 17-hydroxysteroids were decreased (about 10%), suggesting suppression of the HPA axis under these conditions. Plasma cortisol levels have also been demonstrated to decrease in pediatric patients treated twice daily for 3 weeks without occlusion. If HPA axis suppression is noted, an attempt should be made to withdraw the drug, to reduce the frequency of application, or to substitute a less potent corticosteroid. Recovery of HPA axis function is generally prompt upon discontinuation of topical corticosteroids. Infrequently, signs and symptoms of glucocorticosteroid insufficiency may occur, requiring supplemental systemic corticosteroids. For information on systemic supplementation, see prescribing information for those products. Pediatric patients may be more susceptible to systemic toxicity from equivalent doses due to their larger skin surface area to body mass ratios (see **PRECAUTIONS: Pediatric Use**). If irritation develops, alclometasone dipropionate cream should be discontinued and appropriate therapy instituted. Allergic contact dermatitis with corticosteroids is usually diagnosed by observing a failure to heal rather than noting a clinical exacerbation, as with most topical products not containing corticosteroids. Such an observation should be corroborated with appropriate diagnostic patch testing.

If concomitant skin infections are present or develop, an appropriate antifungal or antibacterial agent should be used. If a favorable response does not occur promptly, use of alclometasone dipropionate cream should be discontinued until the infection has been adequately controlled.

In a transgenic mouse study, chronic use of alclometasone dipropionate cream led to an increased number of animals with benign neoplasms of the skin at the treatment site (see **PRECAUTIONS:**

Carcinogenesis, Mutagenesis, and Impairment of Fertility). The clinical relevance of the findings in animal studies to humans is not clear.

Information for Patients: Patients using topical corticosteroids should receive the following information and instructions:

1. This medication is to be used as directed by the physician. It is for external use only. Avoid contact with the eyes.
2. This medication should not be used for any disorder other than that for which it was prescribed.
3. The treated skin area should not be bandaged, otherwise covered or wrapped so as to be occlusive, unless directed by the physician.
4. Patients should report to their physician any signs of local adverse reactions.
5. Parents of pediatric patients should be advised not to use alclometasone dipropionate cream in the treatment of diaper dermatitis.
Alclometasone dipropionate cream should not be applied in the diaper area as diapers or plastic pants may constitute occlusive dressing (see **DOSAGE AND ADMINISTRATION**).
6. This medication should not be used on the face, underarms, or groin areas unless directed by the physician.
7. As with other corticosteroids, therapy should be discontinued when control is achieved. If no improvement is seen within 2 weeks, contact the physician.

Laboratory Tests: The following tests may be helpful in evaluating patients for HPA axis suppression: ACTH stimulation test, A.M. plasma cortisol test, Urinary free cortisol test.

Carcinogenesis, Mutagenesis, Impairment of Fertility: Systemic long-term animal studies have not been performed to evaluate the carcinogenic potential of alclometasone dipropionate. The effects of alclometasone dipropionate on mutagenesis or fertility have not been evaluated.

In a 26-week dermal carcinogenicity study conducted in transgenic (Tg.AC) mice, topical application once daily of both the vehicle cream and the 0.05% alclometasone dipropionate cream significantly increased the incidence of benign neoplasms of the skin in both sexes at the treatment site when compared to untreated controls. This suggests that the positive effect may be associated with the vehicle application. The clinical relevance of the findings in animals to humans is not clear.

Pregnancy: Teratogenic Effects: Pregnancy Category C: Corticosteroids have been shown to be teratogenic in laboratory animals when administered systemically at relatively low dosage levels. Some corticosteroids have been shown to be teratogenic after dermal application in laboratory animals. There are no adequate and well-controlled studies in pregnant women. Alclometasone dipropionate cream should be used during pregnancy only if the potential benefit justifies the potential risk to the fetus.

Nursing Mothers: Systemically administered corticosteroids appear in human milk and could suppress growth, interfere with endogenous corticosteroid production, or cause other untoward effects. It is not known whether topical administration of topical corticosteroids could result in sufficient systemic absorption to produce detectable quantities in human milk. Because many drugs are excreted in human milk, caution should be exercised when alclometasone dipropionate cream is administered to a nursing woman.

Pediatric Use: Alclometasone dipropionate cream may be used with caution in pediatric patients 1 year of age or older, although the safety and efficacy of drug use for longer than 3 weeks have not been established. Use of alclometasone dipropionate cream is supported by results from adequate and well-controlled studies in pediatric patients with corticosteroid-responsive dermatoses. Since the safety and efficacy of alclometasone dipropionate cream has not been established in pediatric patients below 1 year of age, its use in this age-group is not recommended. Because of a higher ratio of skin surface area to body mass, pediatric patients are at a greater risk than adults of HPA axis suppression and Cushing's syndrome when they are treated with topical corticosteroids. They are therefore also at

greater risk of adrenal insufficiency during and/or after withdrawal of treatment. Adverse effects, including striae, have been reported with inappropriate use of topical corticosteroids in infants and children. Pediatric patients applying alclometasone dipropionate cream to >20% of the body surface area are at higher risk for HPA axis suppression. HPA axis suppression, Cushing's syndrome, linear growth retardation, delayed weight gain, and intracranial hypertension have been reported in pediatric patients receiving topical corticosteroids. Manifestations of adrenal suppression in pediatric patients include low plasma cortisol levels and absence of response to ACTH stimulation. Manifestations of intracranial hypertension include bulging fontanelles, headaches, and bilateral papilledema. Alclometasone dipropionate cream should not be used in the treatment of diaper dermatitis.

Geriatric Use: A limited number of patients at or above 65 years of age have been treated with alclometasone dipropionate cream in US clinical trials. The number of patients is too small to permit separate analysis of efficacy and safety. A single adverse reaction reported with alclometasone dipropionate cream in this population was similar to those reactions reported by younger patients. Based on available data, no adjustment of dosage of alclometasone dipropionate cream in geriatric patients is warranted.

ADVERSE REACTIONS:

The following local adverse reactions have been reported with alclometasone dipropionate cream in approximately 2% of patients: itching, burning, erythema, dryness, irritation, and papular rashes. The following additional local adverse reactions have been reported infrequently with topical corticosteroids, but may occur more frequently with the use of occlusive dressings. These reactions are listed in approximate decreasing order of occurrence: folliculitis, acneiform eruptions, hypopigmentation, perioral dermatitis, allergic contact dermatitis, secondary infection, skin atrophy, striae, and miliaria.

OVERDOSAGE:

Topically applied alclometasone dipropionate cream can be absorbed in sufficient amounts to produce systemic effects (see **PRECAUTIONS**).

DOSAGE AND ADMINISTRATION:

Apply a thin film of alclometasone dipropionate cream to the affected skin areas two or three times daily; massage gently until the medication disappears. Alclometasone dipropionate cream may be used in pediatric patients 1 year of age or older. Safety and effectiveness of alclometasone dipropionate cream in pediatric patients for more than 3 weeks of use have not been established. Use in pediatric patients under 1 year of age is not recommended. As with other corticosteroids, therapy should be discontinued when control is achieved. If no improvement is seen within 2 weeks, reassessment of diagnosis may be necessary. Alclometasone dipropionate cream should not be used with occlusive dressings unless directed by a physician. Alclometasone dipropionate cream should not be applied in the diaper area if the child still requires diapers or plastic pants as these garments may constitute occlusive dressing.

Geriatric Use: In studies where geriatric patients (65 years of age or older, see **PRECAUTIONS**) have been treated with alclometasone dipropionate cream, safety did not differ from that in younger patients; therefore, no dosage adjustment is recommended.

HOW SUPPLIED:

Alclometasone dipropionate cream USP, 0.05% is supplied in

15 gram tube NDC 0168-0263-15

45 gram tube NDC 0168-0263-45

60 gram tube NDC 0168-0263-60

Store between 2° and 30°C (36° and 86°F).

E. FOUGERA & CO.

A division of Fougera Pharmaceuticals Inc.
Melville, New York 11747

I2263D

R08/12

#69

PACKAGE LABEL – PRINCIPAL DISPLAY PANEL – 15 G CONTAINER

NDC 0168-0263-15

FOUGERA®

ALCLOMETASONE
DIPROPIONATE CREAM
USP, 0.05%

Rx only

FOR DERMATOLOGIC USE ONLY

NOT FOR OPHTHALMIC USE

WARNING: Keep out of reach of children.

NET WT 15 grams

NDC 0168-0263-15

**Alclometasone
Dipropionate Cream
USP, 0.05%**

**FOR DERMATOLOGIC USE ONLY
NOT FOR OPHTHALMIC USE**

fougera®

Usual Dosage: Apply a thin film of cream to the affected skin areas two or three times daily.

See package insert for full prescribing information.

Store between 2° and 30°C (36° and 86°F).

KEEP OUT OF THE REACH OF CHILDREN.

TO OPEN: Use cap to puncture seal.

IMPORTANT: Do not use if seal has been punctured or is not visible.

R only

Each gram contains: Alclometasone dipropionate 0.5 mg in a hydrophilic, emollient cream base of propylene glycol, white petrolatum, cetostearyl alcohol, glyceryl monostearate, PEG 100 stearate, ceteth-20, monobasic sodium phosphate, chlorocresol, phosphoric acid, and purified water.

NET WT 15 grams

See crimp of tube for Lot Number and Expiration Date.

E. FOUGERA & CO.

A division of Fougera Pharmaceuticals Inc.
Melville, New York 11747

U5222C R01/18



#69



PACKAGE LABEL – PRINCIPAL DISPLAY PANEL – 15 G CARTON

NDC 0168-0263-15

FOUGERA®


ALCLOMETASONE DIPROPIONATE
CREAM USP, 0.05%

Rx only

NOT FOR OPHTHALMIC USE
FOR DERMATOLOGIC USE ONLY

WARNING: Keep out of reach
of children.

NET WT 15 grams



ALCLOMETASONE DIPROPIONATE

alclometasone dipropionate cream

Product Information

Product Type	HUMAN PRESCRIPTION DRUG	Item Code (Source)	NDC:0168-0263
Route of Administration	TOPICAL		

Active Ingredient/Active Moiety

Ingredient Name	Basis of Strength	Strength
ALCLOMETASONE DIPROPIONATE (UNII: S56PQL4N1V) (ALCLOMETASONE - UNII:136H45TB7B)	ALCLOMETASONE DIPROPIONATE	0.5 mg in 1 g

Inactive Ingredients

Ingredient Name	Strength
CETOSTEARYL ALCOHOL (UNII: 2DMT128M1S)	
CETETH-20 (UNII: I835H2IHHX)	
POLYETHYLENE GLYCOL 4500 (UNII: TVH7653921)	
GLYCERYL MONOSTEARATE (UNII: 230OU9XXE4)	
CHLORO CRESOL (UNII: 36W53O7109)	
PETROLATUM (UNII: 4T6H12BN9U)	
WATER (UNII: 059QF0K00R)	
SODIUM PHOSPHATE, MONOBASIC, UNSPECIFIED FORM (UNII: 3980JIH2SW)	
PHOSPHORIC ACID (UNII: E4GA8884NN)	
PROPYLENE GLYCOL (UNII: 6DC9Q167V3)	

Packaging

#	Item Code	Package Description	Marketing Start Date	Marketing End Date
1	NDC:0168-0263-15	15 g in 1 TUBE; Type 0: Not a Combination Product	07/12/2005	
2	NDC:0168-0263-45	45 g in 1 TUBE; Type 0: Not a Combination Product	07/12/2005	
3	NDC:0168-0263-60	60 g in 1 TUBE; Type 0: Not a Combination Product	07/12/2005	

Marketing Information

Marketing Category	Application Number or Monograph Citation	Marketing Start Date	Marketing End Date
ANDA	ANDA076973	07/12/2005	

Labeler - E. Fougera & Co. a division of Fougera Pharmaceuticals Inc. (043838424)

Revised: 9/2019

E. Fougera & Co. a division of Fougera Pharmaceuticals Inc.